Efficacy of Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Abstract

There have been few reports on efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients. In this study, we evaluated the efficacy of aprepitant in patients aged 7-16 years. Between June 2011 and June 2012, 9 patients with hematologic malignancy and osteosarcoma who had received highly and moderately emetogenic chemotherapy with methotrexate (≥1000 mg/m 2), cytarabine (≥2000 mg/m 2), cyclophosphamide (≥200 mg/m 2